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Abstract
Objective: Although a-klotho is known as an anti-aging, antioxidant, and cardio-renal protective protein, the clinical
implications of soluble a-klotho levels in patients with diabetes have not been evaluated. Therefore, this study evaluated
whether plasma and urinary a-klotho levels are associated with albuminuria in kidney disease in diabetes.
Research Design and Methods: A total of 147 patients with type 2 diabetes and 25 healthy control subjects were enrolled.
The plasma and urine concentrations of a-klotho were analyzed by enzyme-linked immunosorbent assay.
Results: Plasma a-klotho (572.4 pg/mL [95% CI, 541.9–604.6 pg/mL] vs. 476.9 pg/mL [95% CI, 416.9–545.5 pg/mL]) and
urinary a-klotho levels (59.8 pg/mg creatinine [95% CI, 43.6–82.0 pg/mg creatinine] vs. 21.0 pg/mg creatinine [95% CI, 9.7–
45.6 pg/mg creatinine]) were significantly higher in diabetic patients than non-diabetic controls. Among diabetic patients,
plasma a-klotho concentration was inversely associated with albuminuria stages (normoalbuminuria, 612.6 pg/mL [95% CI,
568.9–659.6 pg/mL], microalbuminuria, 551.8 pg/mL [95% CI, 500.5–608.3 pg/mL], and macroalbuminuria, 505.7 pg/mL
[95% CI, 439.7–581.7 pg/mL] (p for trend = 0.0081), while urinary a-klotho levels were remained constantly high with
increasing urinary albumin excretion.
Conclusions: Soluble a-klotho levels in plasma and urine may be novel and useful early markers of diabetic renal injury.
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Introduction
Although a-klotho was first described as an anti-aging factor,
recent experimental and clinical studies suggest a-klotho also has
important pleotroic effects on the kidneys [1]. Soluble a-klotho is
derived from the proteolytic cleavage of the extracellular portion
of the membrane-bound a-klotho; alternatively, it can be
generated directly by the alterative splicing of the a-klotho
transcript [2]. It can be measured in blood, urine, and
cerebrospinal fluid [1]. Animals with chronic kidney disease have
very low renal, plasma, and urinary a-klotho levels [3].
Furthermore, humans with chronic kidney disease exhibit
markedly reduced a-klotho in serum [4] and urine [3,5] in the
early stages of kidney disease, progressively decreasing in more
advanced stages.
However, with regard to diabetic nephropathy, the role of a-
klotho in the pathogenesis of kidney injury has not been fully
studied. Renal a-klotho expression is markedly decreased in
diabetic nephropathy in humans and mice [6–8]. A similar decline
is observed in kidney cells treated with methylglyoxal-modified
albumin [8]. These findings collectively suggest renal a-klotho
deficiency is part of an underlying mechanism involved in diabetic
kidney injury. However, the actual role of soluble a-klotho in
diabetic kidney disease has not been evaluated.
This study determined whether diabetes influences soluble
circulating or urinary a-klotho level and investigated the
relationship between these soluble a-klotho levels and albuminuria
in patients with type 2 diabetes.
Research Design And Methods
Ethics statement
This study was carried out in accordance with the Declaration
of Helsinki and study protocol was approved by the Institutional
Review Board of Pusan National University Hospital (Busan,
Korea). All patients provided their written informed consent
before entering the study. Data are available to all interested
researchers on request to the Institutional Review Board of Pusan
National University Hospital.
PLOS ONE | www.plosone.org 1 August 2014 | Volume 9 | Issue 8 | e102984
Subjects
A total of 147 consecutive patients with type 2 diabetes were
enrolled at outpatient clinics between February 2010 and
February 2012. All patients met the following inclusion criteria:
age $18 years and estimated GFR (eGFR) $60 mL min21
1.73 m22, serum creatinine ,1.2 mg/dL, stable renal function
status without 2-fold elevation of serum creatinine for at least 5
months, and no history of administration of RAS inhibitors. If
patients took RAS inhibitors, these medications were withdrawn
and replaced with other antihypertensive agents for at least 2
months before enrollment in this study. A random spot urine
sample and a blood sample were obtained from each patient at the
clinic visit. Medical histories and anthropometric measurements
were also recorded on the same day. The eGFR was calculated
using the Modification of Diet in Renal Disease (MDRD) Study
formula as follows: MDRD =1866 (serum creatinine [mg/
dL])21.1546age [years]20.203 [9]; a correction factor of 0.742 was
used for women.
Patients with active urinary tract infection; renal disease other
than diabetic nephropathy; neoplastic disorders; severe liver
dysfunction; active or chronic infection or inflammatory disorders;
pregnancy; or a recent (i.e., within 6 months) history of acute
myocardial infarction, stroke, or occlusive peripheral vascular
disease were excluded. Nondiabetic control subjects were
randomly selected from the Center for Health Promotion at
Pusan National University Hospital for a comprehensive medical
check-up. They were enrolled in this study if they had fasting
plasma glucose levels of ,100 mg/dL after an overnight fasting,
eGFR of $60 mL min21 1.73 m22 and had no prior history of
diabetes, renal disease or cardiovascular diseases including
hypertension and dyslipidemia.
Soluble a-klotho enzyme-linked immunosorbent assays
Plasma samples were centrifuged for 15 minutes at 3,000 rpm
within 30 minutes of collection; plasma was removed and stored at
270uC until analysis. Urine samples were centrifuged for 10
minutes at 3,000 rpm to remove particulate matter and stored at
270uC until analysis. The plasma and urine concentrations of a-
klotho were analyzed by human soluble a-klotho immunoassay kits
(Immuno-Biological Laboratories, Gunma, Japan) according to
the manufacturer’s protocol. All samples were run in duplicate and
were within the range of the standard curve (93.75–6,000 pg/mL).
Values below the detection limit (6.15 pg/mL) were approximated
using the mean value between zero and the lower limit of
detection. The intra- and inter-assay coefficients of variation were
less than 10%. The levels of urinary a-klotho were expressed as the
ratio of urinary a-klotho to urinary creatinine in order to assess the
hydration states and renal functions of the patients.
Statistical analysis
Categorical variables, continuous variables with a normal
distribution, and non-normally distributed variables are presented
as number (percentage), mean 6 SD, and median (interquartile
range), respectively. Statistical analyses were performed after log-
transforming the data of all skewed variables. Geometric means
(i.e., antilogarithms of the transformed means) are presented with
95% CIs. The significance of differences between continuous
variables was tested by ANOVA or the Kruskal–Wallis test, with
polynomial contrasts for linear trends or Tukey’s multiple
comparison test where appropriate. Categorical variables were
analyzed using the Pearson x2 test. Pearson correlation analysis
was used to determine the correlations between individual
variables. Multivariate regression analyses were used to determine
the associations of plasma a-klotho with several parameters. All
statistical analyses were performed using SPSS version 15.0 (SPSS
Inc., Chicago, IL). The level of significance was set at p,0.05. All
hypothesis tests were 2-sided.
Results
Elevated plasma and urinary a-klotho levels in patients
with type 2 diabetes
A total of 172 subjects were enrolled in this study; their mean
age was 55.8610.4 years (range, 24–82 years), and there were 77
men and 95 women. Age, systolic, diastolic blood pressure, alanine
aminotransferase, insulin, and eGFR were significantly higher in
diabetic patients than non-diabetic control. Meanwhile, hemoglo-
bin, total bilirubin, and direct bilirubin were significantly lower in
diabetic patients than in non-diabetic controls. Other parameters
did not differ significantly between the diabetes group and non-
diabetic controls (Table 1). Plasma a-klotho was significantly
higher in diabetic patients (Fig. 1A, 572.4 pg/mL [95% CI,
541.9–604.6 pg/mL] vs. 476.9 pg/mL [95% CI, 416.9–
545.5 pg/mL], p=0.016). Urinary a-klotho levels were also
significantly higher in diabetic patients than in non-diabetic
controls (Fig. 1C, 59.8 pg/mg creatinine [95% CI, 43.6–82.0 pg/
mg creatinine] vs. 21.0 pg/mg creatinine [95% CI, 9.7–45.6 pg/
mg creatinine], p=0.006).
Inverse correlation between plasma a-klotho levels and
albuminuria in patients with type 2 diabetes
Categories of progressively worse albuminuria were linearly
associated with lower plasma a-klotho levels. The diabetic patients
were categorized into 3 groups according to urine albumin
creatinine ratio (ACR): ACR ,30 mg/g creatinine (normoalbu-
minuria group, n=75), ACR 30–299 mg/g creatinine (microal-
buminuria group, n=42), and ACR $300 mg/g creatinine
(macroalbuminuria group, n=30) (Table 2). Age, sex, BMI,
diastolic blood pressure, aspartate aminotransferase, alanine
aminotransferase, HDL cholesterol, uric acid, phosphorous, serum
creatinine, eGFR, C-reactive protein, and insulin did not differ
significantly among the 3 groups.
The mean plasma a-klotho concentration in the normoalbumi-
nuria group was 612.58 pg/mL compared to 505.70 pg/mL in
the macroalbuminuria group (average difference, 106.88 pg/mL).
Fig. 1 shows a clear inverse association between plasma a-klotho
level and albuminuria level. Plasma a-klotho concentrations were
the highest in the normoalbuminuria group and tended to
decrease with increasing degrees of albuminuria (Fig. 1B, p for
linear trend = 0.008). In contrast to plasma a-klotho levels, no
albuminuria level was significantly associated with urinary a-
klotho creatinine ratio (Fig. 1D).
Correlations between plasma a-klotho levels and other
parameters in patients with type 2 diabetes
As shown in Table 3, plasma a-klotho was significantly
correlated with hemoglobin, aspartate aminotransferase, alanine
aminotransferase, and insulin. Meanwhile, plasma a-klotho was
negatively correlated with phosphorus, urine protein creatinine
ratio, and urine ACR (P,0.05). However, there were no
significant correlations between plasma a-klotho and HbA1C,
eGFR, or urine a-klotho. We performed multivariate regression
analyses for the associations of plasma a-klotho with several
parameters. In a multiple linear regression analysis, plasma a-
klotho was significantly associated with hemoglobin (r=0.01344,
P=0.0095) and urine ACR (r=0.00154, P,0.0001, Table 4).
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Conclusions
This study is the first to demonstrate the plasma and urine levels
of soluble a-klotho are significantly elevated in the diabetic
patients with relatively preserved renal function compared to
control subjects. The results also show plasma a-klotho levels
decreased in proportion to urinary albumin excretion, although
urinary a-klotho levels were stable with increasing urinary albumin
excretion.
a-Klotho is a single-pass transmembrane protein that is highly
expressed in the kidneys and is known to act as a co-receptor for
fibroblast growth factor-23 [1]. Circulating soluble a-klotho can be
generated directly by the alterative splicing of the a-klotho
transcript or the extracellular domain of membrane a-klotho can
be released from membrane-anchored a-klotho on the cell surface
[2]. Unlike membrane a-klotho, which functions as a co-receptor
for fibroblast growth factor-23, soluble a-klotho acts as a hormonal
factor and plays important roles in anti-aging, anti-oxidation, ion
transport modulation, and Wnt signaling. Previous studies aiming
to clarify the role of a-klotho as a potential biomarker of kidney
injury show the blood and urinary concentrations of a-klotho
decrease early in the course of chronic kidney disease in mice with
experimentally induced chronic kidney disease [3] as well as
humans [4]. Although blood a-klotho concentration was found to
be linearly associated with eGFR in previous studies [3,4], plasma
a-klotho was not associated with the eGFR in the present study.
The reason for this discrepancy is that only patients with an eGFR
.60 mL min21 1.73 m22 were enrolled; the geometric mean of
eGFR was 90.6 mL min21 1.73 m22 in the present study. The
concentration of a-klotho in human urine is estimated to be 20–
200 pM [10]. Urinary a-klotho is known to be correlated with
eGFR and is reported to be a surrogate marker of functioning
nephrons in the patients with chronic kidney disease [3,5]. The
present finding that urinary a-klotho was higher in the diabetic
patients whose eGFR is also higher than that of normal people,
further corroborates this.
Meanwhile, little is known about circulating a-klotho levels in
diabetes-related nephropathy. Recent studies in patients with
diabetes report conflicting data. One study found serum a-klotho
level was not significantly different between patients with diabetes
without nephropathy and non-diabetic controls [11,12]. In
contrast, another study reports a significant reduction in serum
klotho levels in patients with glycated hemoglobin (HbA1c) levels
$6.5% compared to control samples (HbA1c ,6.5%) [13].
Kacso et al. [12] report a-klotho decreases in early chronic
kidney disease and increases thereafter in the diabetic patient.
However, they did not evaluate the association between soluble a-
klotho levels and the extent of albuminuria in the early stage of
diabetic nephropathy, specifically in patients with normal renal
function. Asai et al. previously showed that renal a-klotho levels
were significantly decreased in early diabetic nephropathy patients
[7], however, they’ve never compared renal a-klotho levels
between diabetic patients and normal control. They’ve just
showed reduction in renal a-klotho levels in diabetic nephropathy
patients than patients with minimal change disease or IgA
nephropathy. Furthermore, the mean age of diabetic nephropathy
patients was significantly older than patients with minimal change
disease and IgA nephropathy. They also showed that renal a-
klotho levels were significantly decreased in diabetic mice at 8
Table 1. Clinical characteristics and laboratory findings of non-diabetic control subjects and type 2 diabetic patients.
Normal (n=25) DM (n=147) P-value{
Age, years 50.967.6 56.6610.6 0.0101
Sex, male 14(56.0) 63(42.9) 0.2218
BMI, kg/m2 23.462.9 23.563.4 0.8408
SBP, mmHg 119.4614.3 126.3614.8 0.0333
DBP, mmHg 74.467.9 79.0610.3 0.0335
Hemoglobin, g/dL 14.761.6 13.361.6 0.0002
Albumin, g/dL 4.560.3 4.460.5 0.2321
AST, IU/L 22.266.1 23.1611.5 0.5364
ALT, IU/L 18.466.0 24.7616.9 0.0009
Total cholesterol, mg/dL 193.68633.60 180.03640.64 0.1141
HDL cholesterol, mg/dL 55.32613.42 50.04616.87 0.1392
Triglycerides, mg/dL* 110.35(87.61 138.99) 140.78(126.98 156.09) 0.0726
Total bilirubin, mg/dL 1.0760.36 0.6460.21 ,.0001
Direct bilirubin, mg/dL 0.2160.07 0.1460.05 0.0002
Uric acid, mg/dL 5.1060.91 4.7561.31 0.1027
Calcium, mg/dL 9.4460.45 9.3660.49 0.4258
Phosphorus, mg/dL 3.5060.63 3.6560.60 0.2621
Serum creatinine, mg/dL 0.8560.14 0.8060.17 0.1885
eGFR, mL/min/1.73 m2* 85.49(81.70 89.45) 90.62(87.4293.94) 0.0449
C-reactive protein, mg/L* 0.05 (0.04 0.08) 0.08 (0.06 0.09) 0.1924
Insulin, mIU/mL 1.24(0.63 2.23) 5.83(3.35 11.62) ,.0001
Values are mean 6 SD, number of patients (%), median (interquartile range), and geometric means (95% CI) unless otherwise indicated. DM, diabetes mellitus; SBP,
systolic blood pressure; DBP, diastolic blood pressure; AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate. *P-
values were calculated using log-transformed values. {P-values were calculated by Student’s t-test, Mann-Whitney u-test or Pearson x2 test where appropriate.
doi:10.1371/journal.pone.0102984.t001
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weeks after development of diabetes mellitus. They showed that
albuminuria was increased at 2, 4, 6, and 8 weeks after onset of
diabetes, however, renal a-klotho levels were not decreased until 4
weeks after development of diabetes. And they’ve not reported the
renal a-klotho levels in early stage of albuminuric diabetic mice
before 4 weeks of diabetes.
Zhao et al. showed decreased renal klotho expression in db/db
mouse [8]. Although they did not indicate the levels of
albuminuria or renal function data, they used db/db mouse at 20
weeks of age, which is regarded as relatively late stage of diabetic
nephropathy. Deveraj et al. reported that soluble fraction of klotho
was decreased in diabetic patients than non-diabetic controls,
however they never mentioned the albuminuria status of their
diabetic patients [13]. According to our data, there was a clear
inverse association between plasma a-klotho level and albuminuria
level in diabetic patients with relatively preserved renal function.
van Ark J et al. measured circulating a-klotho levels in diabetes
patients. Although they reported that circulating a-klotho levels
were not changed in diabetic patients compared to control, their
sample size was very small (n=35) and they never mentioned the
albuminuria status of their diabetic patients [11]. In the present
study, plasma a-klotho levels in patients with type 2 diabetes were
highest in the normoalbuminuria stage and decreased with
increasing urinary albumin excretion. It is surprising that the
plasma a-klotho levels in the macroalbuminuria group were still
comparable with those in the non-diabetic controls.
Both acute kidney injury and chronic kidney disease exhibit
renal and systemic a-klotho deficiency. Levels of a-klotho
plummet very early and severely in acute kidney injury,
representing a pathogenic factor that exacerbates acute kidney
damage [14]. In chronic kidney disease, a-klotho deficiency
significantly impacts the progression of renal disease as well as
extrarenal complications [3,4]. Meanwhile, soluble a-klotho levels
Figure 1. Plasma (A,B) and urine (C,D) levels of soluble a-klotho in normal participants (n=25) and patients with type 2 diabetes
(n=147). Plasma and urine a-klotho levels were higher in diabetes patients with relatively preserved renal function than the non-diabetic controls
(A,C). The diabetes patients were categorized into 3 groups according to urine ACR: ACR,30 mg/g creatinine (normoalbuminuria group, n= 75), ACR
30–299 mg/g creatinine (microalbuminuria group, n= 42), and ACR $300 mg/g creatinine (macroalbuminuria group, n= 30). Plasma a-klotho levels
decreased in proportion to urinary albumin excretion, although urinary a-klotho levels were stable with increasing urinary albumin excretion (B,D).
Data of non-diabetic control are expressed as a shaded area for the reference (B, D). Data are presented as geometric means and 95% CIs as an error
bar plot. P-values calculated using the log-transformed values are shown in the graph. normo; normoalbuminuria, micro; microalbuminuria, macro;
macroalbuminuria.
doi:10.1371/journal.pone.0102984.g001
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in plasma and/or urine may serve as early biomarkers of kidney
parenchymal injury [15].
Recent studies indicate the potential contribution of absolute a-
klotho deficiency to acute and chronic kidney injury [14,15].
Emerging evidence suggests a-klotho deficiency is an early
biomarker of kidney disease as well as a pathogenic factor. a-
Klotho deficiency is associated with progression and chronic
complications in chronic kidney disease, including vascular
calcification, cardiac hypertrophy, and secondary hyperparathy-
roidism; in particular, a-klotho deficiency induces resistance to
fibroblast growth factor-23 and predisposition to hyperphospha-
temia, which represents a critical feature of chronic kidney disease
[1]. In the present study, plasma a-klotho concentrations tended to
decrease with increasing degrees of albuminuria. Surprisingly,
plasma a-klotho levels in diabetes-related nephropathy were still
not lower than those in the normal controls, whereas they were
lower in chronic kidney disease patients than normal controls in
previous studies. Although absolute plasma a-klotho levels were
not lower than normal, it is possible these levels are insufficient to
prevent albuminuria in the microalbuminuria and macroalbumin-
uria stages of diabetes-related kidney disease. The results of the
present study may help further elucidate the role of a-klotho in the
development and progression of albuminuria in type 2 diabetes.
It is worth noting that the significance of urine a-klotho
concentration as an early biomarker has not been evaluated in
chronic kidney disease. The most important finding of the present
study is that for the first time, high urine a-klotho levels were
found to be associated with diabetes in humans even in the
normoalbuminuria stage.
Nevertheless, the underlying mechanisms explaining the present
results require further investigation. The present results may be
explained by increased a-klotho synthesis or its cleavage process,
although requires further study. The extracellular domain of a-
klotho protein is subject to ectodomain shedding and is released
into the blood and urine [1]; therefore, it may function as a
hormone [16]. Hyperglycemia does not affect renal a-klotho
Table 2. Baseline clinical and laboratory parameters in patients with type 2 diabetes according to albuminuria status.
Normoalbuminuria (n=75) Microalbuminuria (n=42) Macroalbuminuria (n=30) P-value{
Age, years 56.8610.5 56.9611.9 55.869.1 0.8995
Sex, male 31(41.3) 15(35.7) 17 (56.7) 0.1938
Duration of diabetes, years 4ab(2–6) 8a(5–14) 9b(6–15) 0.0007
Diabetic retinopathy, % 17(22.7) 19(45.2) 17(56.7) 0.0016
Diabetic neuropathy, % 8(10.7) 20(47.6) 13(43.3) ,.0001
BMI, kg/m2 23.463.0 23.764.2 23.463.4 0.8957
SBP, mmHg 123.5a612.0 126.1612.3 133.4a621.2 0.0077
DBP, mmHg 78.068.8 78.3610.5 82.5612.6 0.1073
HbA1c, % 7.8
ab61.4 8.4a61.6 8.6b62.0 ,.0001
Glycated albumin, %* 18.40ab(17.24 19.64) 24.32a(22.15 26.70) 21.87b(18.68 25.61) ,.0001
Hemoglobin, g/dL 13.6a61.3 13.361.6 12.7a62.2 0.0297
Albumin, g/dL 4.5a60.3 4.4b60.4 4.1ab60.7 ,.0001
AST, IU/L 23.368.7 23.0614.3 22.9613.2 0.9882
ALT, IU/L 24.7613.6 25.2621.2 23.8618.5 0.9417
Total cholesterol, mg/dL 170.44a637.18 181.57637.83 201.87a645.03 0.0013
LDL cholesterol, mg/dL 98.6a630.6 111.2634.4 123.8a657.7 0.0090
HDL cholesterol, mg/dL 49.0615.7 49.9612.9 52.8623.7 0.5944
Triglycerides, mg/dL* 128.11a(110.14 149.01) 139.63(117.92 165.33) 180.31a(141.72 229.41) 0.0428
Total bilirubin, mg/dL 0.66a60.21 0.67b60.19 0.53ab60.23 0.0067
Direct bilirubin, mg/dL 0.15a60.05 0.15b60.05 0.12ab60.06 0.0076
Uric acid, mg/dL 4.661.2 4.761.4 5.261.3 0.1393
Calcium, mg/dL 9.3960.37 9.44a60.46 9.15a60.72 0.0362
Phosphorus, mg/dL 3.5660.57 3.7360.60 3.7460.67 0.2406
Serum creatinine, mg/dL 0.7960.15 0.7760.16 0.8560.20 0.1387
eGFR, mL/min/1.73 m2* 90.3(86.5 94.2) 92.3(85.7 99.5) 89.2(80.4 98.8) 0.7856
C-reactive protein, mg/L* 0.07(0.05 0.09) 0.09(0.06 0.13) 0.07(0.04 0.12) 0.5280
Insulin, mIU/mL 5.87(3.35 11.62) 5.19(1.49 13.05) 7.54(4.26 11.70) 0.5165
Urine ACR, mg/g* 9.85ab(6.74 9.85) 103.04ac (68.11 103.04) 1131.12bc(609.53 1131.12) ,.0001
Urine PCR, mg/g* 100.67ab(83.22 100.67) 356.16ac(222.33 356.16) 2261.86bc(1146.68 2261.86) ,.0001
Values are mean 6 SD, number of patients (%), median (interquartile range), and geometric means (95% CI) unless otherwise indicated. DR, diabetic retinopathy; DN,
diabetic neuropathy; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglycerides; TB, total bilirubin; DB, direct bilirubin; UA, uric
acid; Ca, calcium; P, phosphorous; Scr, serum creatinine; eGFR, estimated glomerular filtration rate; CRP, C-reactive protein; ACR, Urine albumin creatinine ratio; PCR,
Urine protein creatinine ratio. *P-values were calculated using log-transformed values. {P-values were calculated by ANOVA or Pearson x2 test where appropriate. The
same superscripted letters indicate statistical significance according to Tukey’s multiple comparison test.
doi:10.1371/journal.pone.0102984.t002
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production per se, because high glucose does not alter a-klotho
expression in kidney cells and diabetes does not affect renal a-
klotho mRNA expression in mice [11]. The lack of an association
between HbA1c or glycated albumin with soluble a-klotho
concentrations in the present study also corroborates previous
observations. Insulin can increase soluble a-klotho concentration
through the cleavage and release of the extracellular domain of a-
klotho [17]. In type 2 diabetes at early stage, soluble a-klotho level
Table 3. Correlations between plasma a-klotho levels and other parameters in patients with diabetes (n = 147).
Plasma klotho*
r P-value
BMI, kg/m2 0.098 0.2398
SBP, mmHg 20.013 0.8740
DBP, mmHg 0.046 0.5820
HbA1c, % 0.046 0.5773
Glycated albumin, %* 0.069 0.4076
Hemoglobin, g/dL 0.287 0.0005
Albumin, g/dL 0.050 0.5511
AST, IU/L 0.243 0.0030
ALT, IU/L 0.194 0.0188
Total cholesterol, mg/dL 0.005 0.9547
LDL cholesterol, mg/dL 0.040 0.6308
HDL cholesterol, mg/dL 20.013 0.8763
Triglycerides, mg/dL* 20.116 0.1622
Total bilirubin, mg/dL 0.137 0.0978
Direct bilirubin, mg/dL 0.155 0.0626
Uric acid, mg/dL 20.117 0.1604
Calcium, mg/dL 0.060 0.4671
Phosphorus, mg/dL 20.240 0.0037
Serum creatinine, mg/dL 0.059 0.4749
eGFR, mL/min/1.73 m2* 20.018 0.8265
C-reactive protein, mg/L* 20.080 0.3335
Insulin, mIU/mL 0.183 0.0273
Urine ACR, mg/g* 20.214 0.0093
Urine PCR, mg/g* 20.237 0.0040
Urine klotho, pg/mg* 20.011 0.8967
SBP, systolic blood pressure; DBP, diastolic blood pressure; AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate;
ACR, albumin creatinine ratio; PCR, protein creatinine ratio. *Log transformed data before analysis, r: Pearson correlation coefficient.
doi:10.1371/journal.pone.0102984.t003
Table 4. Multiple linear regression analysis between plasma a-klotho levels and other parameters in patients with diabetes
(n= 147).
Plasma Klotho*
b SE P-value
Age, years 0.00038 0.00066 0.5690
Hemoglobin, g/dL 0.01344 0.00511 0.0095
ALT, IU/L 20.00035 0.00042 0.4047
Phosphorus, mg/dL 0.02243 0.01211 0.0661
Total bilirubin, mg/dL 20.02343 0.03553 0.5108
Insulin, mIU/mL 20.00009 0.00014 0.5321
Urine ACR, mg/g 0.00154 0.00003 ,.0001
Urine PCR, mg/g 0.00000 0.00001 0.9961
ALT, alanine aminotransferase; ACR, albumin creatinine ratio; PCR, protein creatinine ratio. *Log transformed data before analysis.
doi:10.1371/journal.pone.0102984.t004
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is increased in plasma that may result in increased amount of a-
klotho protein in urine. a-Klotho protein is expressed in both
apical and basolateral membrane of kidney tubule [18]. Soluble a-
klotho level may be determined by two possible mechanisms; 1)
cleavage of a-klotho protein by proteases such as ADAM10 or 17
[17] and 2) secretion of splice variant form of a-klotho into blood
or urine. Extracellular domain of a-klotho can be released into
urine and blood from apical and basolateral membranes,
respectively. Insulin receptor is also expressed in both apical and
basolateral membrane of kidney tubular cells. At early stagy of
type 2 diabetes, blood insulin level is increased that can stimulate
the cleavage and release of the extracellular domain of a-klotho
[17] into blood and/or urine. In this study, blood insulin level was
also increased in diabetic patients than non-diabetic controls as
expected. Increased level of soluble a-klotho may be filtered in
glomeruli and present in urine. Cha et al. [10] reported that
intraperitoneal administration of soluble klotho increased urinary
K+ excretion in rat by ROMK channel activation which is
expressed in apical membrane. Interestingly, epitope-tagged
klotho was appeared in urine at 2 hr after intravenous
administration [19] indicating that klotho protein may be filtered
in glomeruli and regulates ROMK channel from luminal side.
We found an interesting decrease in hemoglobin concentration
from 13.6 g/dL in patients with normoalbuminuria to 13.3 g/dL
in patients with microalbuminuria and then low to 12.7 g/dL in
macroalbuminuria (Table 2). The decrease of hemoglobin con-
centration in the absence of significant excretory dysfunction has
also been demonstrated in other study [20]. The decrease in
hemoglobin in macroalbuminuria as compared to normoalbumi-
nuria cannot be explained by reduced renal function as there was
no significant difference in eGFR between the groups (Table 2).
Our and the previous findings may suggest that erythropoietin
deficiency, which has a major etiological role in the anemia
associated with renal failure, begins even before there is evidence
of deterioration in renal function. Other possibility includes
eryptosis. Enhanced eryptosis, suicidal erythrocyte death, is
observed in diabetes [21] and eryptosis is further enhanced in
klotho-deficient mice [22].
Plasma and urinary a-klotho were not correlated in a previous
study [5] or the present study.
Exogenous supplementation or stimulation of endogenous a-
klotho may prevent and/or ameliorate kidney injury and mitigate
chronic kidney disease development. The correction of a-klotho
deficiency may delay the progression and forestall the develop-
ment of extrarenal complications in chronic kidney disease.
Angiotensin II receptor blocker treatment was recently shown to
increase blood a-klotho levels while reducing albuminuria in type
2 diabetes with nephropathy [23,24]. The findings that both
exogenous soluble a-klotho administration and overexpression of
membranous a-klotho in kidney cell culture suppress NF-kB
activation and subsequent inflammatory cytokine production in
the response to TNF-a stimulation suggest a-klotho serves as an
anti-inflammatory modulator [8]. Therefore, preventing deceases
in a-klotho and a-klotho supplementation are potential novel
therapeutic strategies for early diabetic nephropathy. In multiple
experimental models of chronic kidney disease, the replacement or
endogenous upregulation of a-klotho protects the kidneys from
renal insults, preserves kidney function, and suppresses renal
fibrosis. Thus, a-klotho is a highly promising candidate early
biomarker as well as a novel therapeutic agent for chronic kidney
disease [2].
The results of this study are subject to some limitations. First,
the sample size was relatively small. We measured the urinary
levels of a-klotho with single random spot urine samples, although
urine samples were collected at the outpatient clinic from patients
without illness or renal diseases besides diabetic nephropathy;
moreover, a moderate linear association was observed between the
amount of urine a-klotho in 24 hours and urinary a-klotho/
creatinine ratio in random urine specimens (r=0.726, p,0.01)
[5]. Despite these limitations, it is noteworthy that blood and urine
a-klotho concentrations can easily be checked and used to assess
the development of diabetic nephropathy prior to the onset of
microalbuminuria, which is the earliest sign of diabetic nephrop-
athy in clinical settings. Second, In addition, we measured and
evaluated plasma and urinary a-klotho concentrations at a single
time point in this cross-sectional study. Therefore, it is unclear
whether plasma and/or urine a-klotho causes albuminuria in
diabetes. Furthermore, all enrolled patients on medication with
RAS inhibitors had a sufficient washout period for these drugs in
order to role out the effect of RAS inhibitors on plasma and/or
urinary klotho levels and albuminuria.
In conclusion, the results of the present study suggest plasma
and urinary a-klotho may be the early markers for predicting renal
injury in patients with type 2 diabetes and we need to do long-term
prospective study in order to elucidate the role of a-klotho in the
pathophysiological mechanisms of the development and progres-
sion of albuminuria in type 2 diabetes.
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